Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

February 16, 2024

Study Completion Date

February 16, 2024

Conditions
Mild Cognitive Impairment
Interventions
BIOLOGICAL

Plasmapheresis

Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma

BIOLOGICAL

Plasma infusion

Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03887741 - Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression | Biotech Hunter | Biotech Hunter